Corcept (CORT) Down 8.3% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/02/22
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 07/29/22
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian CancerGlobeNewsWire • 06/29/22
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Corcept Therapeutics IncorporatedNewsfile Corp • 06/29/22
Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian CancerGlobeNewsWire • 06/06/22
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/05/22
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain StudyZacks Investment Research • 04/05/22
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight GainGlobeNewsWire • 04/04/22